JKJenneke Keizer-Garritsen

Jenneke Keizer-Garritsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jenneke Keizer-Garritsen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Semi-Quantitative Multiplex Profiling of the Complement System Identifies Associations of Complement Proteins with Genetic Variants and Metabolites in Age-Related Macular Degeneration

    by I. Erkin Acar, Esther Willems, Eveline Kersten, Jenneke Keizer-Garritsen, Else Kragt, Bjorn Bakker, Tessel E. Galesloot, Carel B. Hoyng, Sascha Fauser, Alain J. van Gool, et al.

    Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. The complement system has been identified as one of the main AMD disease pathways. We performed a comprehensive expression analysis of 32 complement proteins in plasma samples of 255 AMD patients and 221 control individuals using mass spectrometry-based semi-quantitative multiplex profiling. We detected significant associations of complement protein levels with age, sex and body-mass index (BMI), and potential associations of C-reactive protein, factor H related-2 (FHR-2) and collectin-11 with AMD. In addition, we confirmed previously described associations and identified new associations of AMD variants with complement levels. New associations include increased C4 levels for rs181705462 at the C2/CFB locus, decreased vitronectin (VTN) levels for rs11080055 at the TMEM97/VTN locus and decreased factor I levels for rs10033900 at the CFI locus. Finally, we detected significant associations between AMD-associated metabolites and complement proteins in plasma. The most significant complement-metabolite associations included increased high density lipoprotein (HDL) subparticle levels with decreased C3, factor H (FH) and VTN levels. The results of our study indicate that demographic factors, genetic variants and circulating metabolites are associated with complement protein components. We suggest that these factors should be considered to design personalized treatment approaches and to increase the success of clinical trials targeting the complement system.


  • Open Access

    Biosynthetic homeostasis and resilience of the complement system in health and infectious disease

    by Esther Willems, Wynand Alkema, Jenneke Keizer-Garritsen, Anouk Suppers, Michiel van der Flier, Ria H.L.A. Philipsen, Lambert P. van Den Heuvel, Elena Volokhina, Renate G. van der Molen, Jethro A. Herberg, et al.


  • Measurement of thiopurine S -methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children

    by Jenneke J. Keizer-Garritsen, Connie Brouwer, Lambert H.J. Lambooy, Patricia Ter Riet, Jos P.M. Bökkerink, Frans J.M. Trijbels, Ronney A. De Abreu

    Background: Monitoring 6-thiopurine S-methyltransferase (TPMT; EC 2.1.1.67) activity is especially important when patients are treated with 6-thiopurine drugs, since severe bone marrow toxicity may be induced if patients have deficient TPMT activity. Methods: We have developed a method based on high-performance liquid chromatography (HPLC) for the measurement of TPMT activity in various cell types: erythrocytes (RBC), human peripheral blood mononuclear cells (pMNC) and human malignant lymphoblasts (Molt-F4). The enzymatic activity is measured by the amount of 6-methylmercaptopurine formed, using 6-mercaptopurine (6MP) as substrate and S-adenosylmethionine as co-substrate. Results: The K m values calculated for 6MP were 0·54 (RBC), 0·85 (pMNC) and 0·65 (Molt-F4 cells) mmol/L. The K m values for S-adenosylmethionine were 11·9 (RBC), 16·4 (pMNC) and 6·65 (Molt-F4 cells) µmol/L. The assay variation was 8·2-17%. TPMT activity was determined in a control group of 103 children and young adults (44 female, 59 male). The values observed were (mean ± standard deviation): female children and young adults, 15·1 ± 4·8 pmol/10 7 cells per h ( n = 44); male children and young adults, 15·8 ± 6·4 pmol/10 7 cells per h ( n = 59). No gender or age differences were found. Conclusion: The HPLC-based method enables the rapid screening of TPMT activities in large groups of patients treated with 6-thiopurines.